Tumor cells express high levels of integrins, which can be labeled using cyclic peptides, but selective labeling of target cells can be a challenge. Here in situ ligation of strongly binding cyclic peptides with weakly binding glycans allows discrimination of cancerous and non-cancerous cells which both express integrins on the surface.
- Shogo Nomura
- Yasuko Egawa
- Katsunori Tanaka
